Beyond Primary Prophylaxis: Assessing the Role of Diagnostic Biomarkers for Predicting High-Risk Episodes in the Febrile Neutropenia Market Segment.
The global Febrile Neutropenia (FN) Market is marked by significant regional disparities, driven primarily by differences in healthcare spending, oncology guideline adherence, and the penetration of biosimilars. North America, especially the United States, represents the largest revenue share. This dominance stems from high rates of cancer diagnosis, robust private and public insurance coverage...
0 Σχόλια 0 Μοιράστηκε 0 Προεπισκόπηση